Carnival halted with news pending

CCL was down 15% premarket at the time of the halt.
https://seekingalpha.com/news/3550990-carnival-halted-news-pending

Princess Cruises pauses operation

In a proactive response to the unpredictable circumstances evolving from the global spread of Covid-19, Princess Cruises says it will voluntarily pause global operations of its 18 cruise ships for 60 days.

Those currently on board a cruise that will end in the next five days will continue to sail as expected through the end of the itinerary so that onward travel arrangements are not disrupted.

Current voyages that are underway and extend beyond March 17 will be ended at the most convenient location for guests, factoring in operational requirements.

“While this is a difficult business decision, we firmly believe it is the right one and is in alignment with our company’s core values. Rest assured the long-serving and dedicated professionals at our company will make best use of this time to prepare Princess Cruises’ fleet of cruise ships for a successful return to operation to serve our guests by delivering an exceptional vacation experience,” CEO Jan Swartz said in a video post.

Related tickers: CCL, NCLH, RCL

https://seekingalpha.com/news/3551016-princess-cruises-pauses-operations

Futures tumble 5%, hit ‘limit down’ halt

S&P 500 and Nasdaq futures fell another 5% in overnight action, hitting the so-called limit down threshold, as the the two indexes look to join the Dow Jones Industrial Average in bear market territory.

The latter, which tumbled another 1,200 points in recent hours, crashed on Wednesday after the WHO classified the coronavirus outbreak as a pandemic for the first time.

Threatening more disruptions to the world economy, President Trump said all travel from Europe to the U.S. would be suspended for 30 days.

Efforts were also announced on deferred tax payments and payroll tax relief, but investors seemed to have been looking for more.

Crude futures are off 4.1% to $31.63/bbl, gold is 0.3% lower at $1636.70 and the 10-year Treasury yield is down 6 bps to 0.77%.

https://seekingalpha.com/news/3550839-futures-tumble-5-hit-limit-down-halt

AstraZeneca Cediranib Phase 3 Trial Didn’t Meet Endpoint

AstraZeneca PLC said Thursday that the Phase 3 GY004 trial for its drug Cediranib didn’t meet its primary endpoint.
The pharmaceutical company said that the trial didn’t meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in progression-free survival with the drug.
In the trial, Cediranib was added to Lynparza in platinum-sensitive relapsed ovarian cancer.
“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” Executive Vice President of Oncology Research and Development Jose Baselga said.
https://www.marketscreener.com/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Cediranib-Phase-3-Trial-Didn-t-Meet-Endpoint-30148223/

Economic remedies for coronavirus

Policymakers and government leaders have taken a range of approaches to deal with the economic fallout from the coronavirus. Here is a list of how some of the world’s biggest economies and economic blocs have reacted.

UNITED STATES
President Donald Trump instructed the U.S. Treasury Department to defer tax payments without interest or penalties for certain individuals and businesses negatively impacted, saying it would provide more than $200 billion of additional liquidity to the economy.
Trump also said he was ordering the Small Business Administration to provide capital and liquidity to firms affected by the coronavirus by providing low-interest loans to small businesses in affected states and territories, effective immediately.
Earlier, Trump signed a $8.3 billion emergency spending bill to combat the spread of the virus and develop vaccines for the highly contagious disease.
The U.S. Federal Reserve has cut interest rates by half a percentage point in its first emergency rate move since the height of the 2008 financial crisis. Investors expect more cuts in the weeks ahead.
CHINA
China said it had earmarked 110.5 billion yuan ($15.9 billion) to fight the epidemic.
Beijing has ramped up funding support for virus-hit regions and the country’s central bank has cut several of its key rates, including the benchmark lending rate, and has urged banks to give cheap loans and payment relief to exposed companies.
China will modify the environmental supervision of companies to help the resumption of production disrupted by the coronavirus epidemic, giving firms more time to rectify environmental problems.
JAPAN
Japan unveiled a second package of measures worth about $4 billion in spending to cope with the fallout of the coronavirus outbreak, focusing on support to small and mid-sized firms, as concerns mount about risks to the fragile economy.
Separately, Bank of Japan Governor Haruhiko Kuroda has pledged to pump more liquidity into markets and step up asset buying.
Japan’s central bank may also take steps to ensure companies hit by the coronavirus outbreak do not face a financial squeeze before the end of the current fiscal year in March, according to sources familiar with the central bank’s thinking.
EUROPEAN CENTRAL BANK
The ECB, the central bank of the euro zone, has so far avoided cutting interest rates. Policymakers did hold an unscheduled meeting on March 3 but it was to discuss operational responses to coronavirus, such as whether to hold events and staff shortages, rather than any policy response, sources close to the matter said.
The ECB has asked euro zone banks to review their business continuity plans and the actions they can take to prepare for and minimize the potential adverse effects of the coronavirus, a letter seen by Reuters shows.
THE EUROPEAN UNION
European Union leaders have so far failed to agree radical measures to tackle the crisis. The head of the bloc’s executive Ursula von der Leyen said the European Commission will set up a joint investment fund with firepower of 25 billion euros ($28 billion) from existing resources to cushion the blow to vulnerable sectors of the bloc’s economies.
GERMANY
Germany’s centre-left coalition agreed to increase public investments by 12.4 billion euros by 2024 and to make it easier for companies to claim subsidies to support workers on reduced working hours to counter the effects of the coronavirus epidemic.
Chancellor Angela Merkel’s conservatives are split over whether Germany should rush out a fiscal stimulus package to counter any impact of the coronavirus on Europe’s largest economy.
Budget experts estimate the government has the fiscal room for additional measures worth at least 17 billion euros ($18.9 billion). Some officials say that Berlin could even put together a stimulus package worth up to 50 billion euros, without ditching the government’s policy of no new debt.
BRITAIN
Britain launched a 30 billion-pound ($39 billion) economic stimulus plan just hours after the Bank of England slashed interest rates, a double-barrelled package aimed at warding off the risk of a coronavirus recession.
The Bank of England cut interest rates by half a percentage point and offered banks cheaper funding and a reduction in capital buffers in an emergency move to bolster Britain’s economy against disruption caused by the coronavirus outbreak.
FRANCE
French Finance Minister Bruno Le Marie has said that Europe needs to be ready to use fiscal stimulus to deal with the impact of the coronavirus.
The government is allowing companies to suspend payments of some social charges and taxes, and is activating state-subsidised short-time work schemes. It has ordered the Bpifrance state investment bank to guarantee loans needed to overcome short-term cashflow problems.
Paris has also allowed companies to declare force majeure due to the outbreak if they cannot honor a contract with the public sector, and is putting pressure on big companies to show similar leniency with subcontractors.
INDIA
The Reserve Bank of India (RBI) plans to infuse fresh cash liquidity into the system through a second round of long-term repo operations (LTRO), government officials told Reuters, amid fears that the coronavirus outbreak will derail any revival of economic growth. One official said the RBI might inject as much as 1 trillion rupees ($13.6 billion) in the round that will begin as early as April.
The RBI has said it stands ready to act to maintain market confidence and preserve financial stability.
The government is, meanwhile, pushing state-run banks to approve new loans amounting to 500-600 billion rupees by the end of March, according to government sources.
ITALY
Prime Minister Giuseppe Conte said on March 11 that he would ramp up spending to soften the economic blow from the virus, allocating 25 billion euros ($28.3 billion) to support firms and families.
Only a week earlier, he estimated Italy would need just 7.5 billion euros.
The extra spending means Italy’s 2020 budget deficit looks certain to climb above 3% of national output, a ceiling set by EU rules.
CANADA
Finance Minister Bill Morneau said on March 9 that the government was “looking at taking some initiatives this week,” as Canada reported its first coronavirus death, with a steep decline in oil prices expected to hit the world’s fourth-largest crude producer hard.
The Bank of Canada lowered its benchmark overnight rate to 1.25% from 1.75% in response to the epidemic, prompting money markets to price in a better-than-even chance of another reduction next month. The last time it cut by 50 basis points was in 2009 during the financial crisis.
SOUTH KOREA
The government announced a stimulus package of 11.7 trillion won ($9.8 billion) to cushion the impact of the largest outbreak of coronavirus outside China.
Finance Minister Hong Nam-ki said the supplementary budget, subject to parliamentary approval, would channel money to the health system, childcare, and outdoor markets. An additional 10.3 trillion won in treasury bonds will be issued this year to fund the extra budget.
Seoul has also dramatically tightened rules on short-selling for three months. Starting March 11, stocks with a sudden and abnormal increase in short-selling transactions will be suspended from further short-selling for 10 days.
AUSTRALIA
Australia’s government said it would pump A$17.6 billion ($11.4 billion) into the economy to try to stop the coronavirus outbreak triggering a recession, its first stimulus package since the 2008 global financial crisis.
The package will subsidise the wages of 120,000 apprentices, offer one-off cash payments for welfare recipients and give up to A$25,000 ($16,160) to small businesses, Prime Minister Scott Morrison said.
https://www.marketscreener.com/news/The-economic-remedies-for-the-coronavirus–30142499/

Selling continues as futures tumble another 4-5%

S&P 500 and Nasdaq Composite futures are growling, off another 4.5% in overnight action, as the the two indexes look to join the Dow Jones Industrial Average, which tumbled into a bear market on Wednesday.

DJIA futures are off another 1,200 points, or 5%, after an address from President Trump failed to quell concerns over a coronavirus-fueled economic slowdown.

All travel to from Europe to the U.S. was suspended for 30 days, threatening more disruptions to the world economy. The SBA was also instructed to provide low interest loans, while efforts were announced on deferred tax payments and payroll tax relief, but investors seemed to have been looking for more.

Crude futures are off 4.1% to $31.63/bbl, gold is 0.3% lower at $1636.70 and the 10-year Treasury yield is down 6 bps to 0.77%.

https://seekingalpha.com/news/3550839-selling-continues-futures-tumble-another-4minus-5

Emergent BioSolutions, Novavax in Pact to Develop, Manufacture Covid-19 Vax

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing into the clinic Novavax’s novel experimental vaccine candidate to protect against coronavirus disease (COVID-19). Under the terms of the agreement, Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses. Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate will be used in a Phase 1 clinical study within the next four months.
Robert G. Kramer Sr., president and chief executive officer at Emergent BioSolutions, stated, “We are pleased with our Novavax collaboration, which reflects Emergent’s commitment to advancing potential solutions to combat coronavirus disease. As we provide our CDMO services, backed by our established track record as a trusted partner to governments, industry, and non-government organizations, we leverage our long history in vaccines and therapeutics development and manufacturing, as well as our broad capabilities focused on medical countermeasures for emerging infectious diseases. The increasing threat of COVID-19 requires a comprehensive response and we continue to evaluate various vaccine, therapeutic, and CDMO approaches to enable us to marshal resources to make a meaningful impact on this global public health emergency.”
In support of the COVID-19 experimental vaccine candidate’s progression into the clinic, Emergent has mobilized its integrated clinical and commercial development and manufacturing network to provide development services out of its Gaithersburg, Md location as well as manufacturing services out of its two Baltimore, Md facilities. Drug substance will be produced at the Baltimore/Bayview location, which is designated by the U.S. Department of Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), while drug product will be produced at the Baltimore/Camden location.
https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing